TFRC and hepatocellular carcinoma: USP22 promotes the proliferation of hepatocellular carcinoma cells by stabilising CDK11B and enhances resistance to Sorafenib by inhibiting ferroptosis through the USP22/H2BK120ub/TFRC axis.